Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.95M$3.95Mderived+544.2% vs Q4 2019 Net Income$1.32M$1.32MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$2,323,000— Operating Incomederived$1,323,000N/M Operating Cash Flowderived$1,831,000N/M Free Cash Flowderived$1,817,000N/M Margins · derivedGross margin58.8%
Operating margin33.5%+167.6 pt vs Q4 2019
Net margin33.5%+167.1 pt vs Q4 2019
ended Jul 31, 2020 · filed Oct 8, 2020 · 69 d after period end